Search Technologies
Displaying 1 - 10 of 13 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Functional Myelination of Neurons
Published Tuesday, May 7, 2024Summary This invention is a significant advancement in regenerative medicine, offering a novel stem cell-based therapy for demyelinating diseases. It utilizes melanocyte stem cells (MeSCs) from the skin to differentiate into cells capable of myelination, addressing diseases like...
Investigator(s): Thomas Hornyak and Sandeep Joshi
Categories: Therapeutics, Biologics, Stem Cells, Methods of Treatment
Docket: TH-2015-020
-
Compositions and Methods for Delivering Nucleic Acids to Cells
Published Wednesday, December 6, 2023Summary This invention provides a breakthrough in gene therapy and molecular biology, featuring a non-viral vector system for delivering nucleic acids to cells. It utilizes a polyplex particle with acetylated polyethylenimine (Ac-PEI) and an anionic biomaterial envelope, reducing...
Investigator(s): Ryan Pearson and Atanu Chakraborty
Categories: Therapeutics, Biologics, Methods of Treatment
Docket: RP-2020-012
-
Muscarinic Antagonists for the Treatment of Depression
Published Monday, June 26, 2023Summary The disclosed technology describes the utilization of muscarinic antagonists for the treatment of depression. Muscarinic antagonists are a class of compounds that block muscarinic acetylcholine receptors to ameliorate...
Investigator(s): Andrew Coop, Jack Bergman, Chad Johnson, Brian Kangas, James Woods, Emily Jukiewicz, Gail Winger
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): depression, Muscarinic Antagonists, Mood Regulation
Docket: AC-2019-107
-
Gallium-salophen Antimicrobial Compounds and Methods of Use Thereof
Published Wednesday, May 24, 2023Summary Pseudomonas aeruginosa (Pa), a WHO priority 1 pathogen, causes life-threatening infections. Multidrug resistant Pa has been classified by the CDC as a “serious...
Investigator(s): Fengtian Xue, Angela Wilks
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): pharmaceuticals, Clinical Medicine, Antimicrobial Compounds
Docket: FX-2020-101
-
Prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof
Published Wednesday, May 17, 2023Summary In summary, the invention disclosed by UMB investigators offers a promising new approach to the treatment of cancer and autoimmune diseases by introducing a series of novel prodrugs with improved safety and efficacy...
Investigator(s): Fengtian Xue, Yan Shu, Yong Li
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): Prodrug, cancer, Autoimmune, Therapeutic
Docket: FX-2019-033
-
Wnt Signaling Pathway Inhibitors for Treatments of Disease
Published Wednesday, May 17, 2023Summary UMB inventors have developed compounds that inhibit the Wnt/β-catenin signaling pathway, which is implicated in various diseases, including cancer and metabolic disorders such as type 2 diabetes, obesity,...
Investigator(s): Fengtian Xue, Yan Shu
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): cancer, Metabolic Disease, diabetes
Docket: FX-2015-082
-
Compounds for Treating Parasitic Infections
Published Monday, May 15, 2023Summary Researchers at the University of Maryland, Baltimore and the University of Maryland, College Park have synthesized a new class of 1,3-thiazolidine-2,4-dione derivatives that exhibit potent activity against several protozoan parasites,...
Investigator(s): Fengtian Xue, Iqbal Hamza
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): Parsitology, infection, Immunology
Docket: FX-2015-021
-
LRP1 Antagonists for Treatment and Prevention of Alzheimer’s Disease
Published Thursday, May 26, 2022Alzheimer’s disease (AD) is a neurodegenerative disease characterized by gradual deterioration of the brain cells and loss of multiple cognitive functions. The cognitive decline in AD is closely linked to aggregated forms of tau which form neurofibrillary tangles (“NFT”) that initiate in the entorhinal cortex...
Investigator(s): Dudley Strickland, Molly Migliorini, Brian Hampton, Joana Cooper, Selen Muratoglu Catania, Bradley Hyman, Aurelien Lathuiliere
Categories: Therapeutics, Methods of Treatment
Keyword(s): Alzheimer’s Disease, Therapeutics, LRP1, Tau, Method, CNS
Docket: DS-2020-052
-
NEU1-Selective Sialidase Inhibitors for Treatment of Idiopathic Pulmonary Fibrosis
Published Thursday, May 12, 2022Idiopathic Pulmonary Fibrosis (IPF) is an unrelenting, uniformly fatal disease in which lung architecture is distorted and replaced by scar tissue, thereby compromising pulmonary function. IPF patients only survive 2 to 3 years after diagnosis. Although numerous host factors have been implicated in IPF pathogenesis, no unified mechanistic...
Investigator(s): Simeon Goldblum; Irina Luzina; Sergei Atamas
Categories: Therapeutics, Methods of Treatment
Keyword(s): Fibrosis, Therapeutics, IPF
Docket: SG-2019-090
-
Correction of Ischemia with p53 Inhibitors: A Novel Therapeutic Approach to Induce Arteriogenesis
Published Friday, February 24, 2017Severe obstruction of the arteries and reduced blood flow (critical limb ischemia(CLI)) is the advanced stage of peripheral artery disease (PAD). Investigators at UMB have found that Pifithrin-α, a p53 pharmacological inhibitor, improves limb perfusion in diabetic animals, suggesting a therapeutic role in CLI. Tumor-suppressing...
Investigator(s): Rajabrata Sarkar, Mark Hoofnagle, Subhradip Mukhopadhyay
Categories: Therapeutics, Methods of Treatment
Keyword(s): cardiovascular
Docket: RS-2013-040